On Sept 2, 2022, the Editorial Office of Journal of Translational Genetics and Genomics (JTGG, Online ISSN: 2578-5281) had the honor to interview Dr. Fred C. Lam from the Saint Elizabeth's Medical Center, Steward Medical Group, Boston, MA, United States.
This interview is initiated on a review article titled "The DNA damage response - from cell biology to human disease" written by Dr. Fred C. Lam in JTGG on May 13, 2022. This article focuses on the current hot topic - DNA damage response and has attracted wide attention on social media.
During the interview, Dr. Lam talked about the current understanding of how these underlying errors in DNA repair contribute to the clinical outcomes of patients with these diseases. Besides, Dr. Lam introduced nanotechnology and precision medicine for the treatment of brain tumors and the application and future prospects of nanotechnology in clinical translation. In addition, he shared some of his insights into academic writing and publication.
Dr. Fred C. Lam is a Canadian board certified neurosurgeon with a PhD in neuroscience. Dr. Lam obtained his neurosurgical fellowship training at Harvard Medical School, specializing in brain and spine tumors. He performed postdoctoral research in cancer biology, DNA damage, and epigenetics at the Koch Institute for Integrative Cancer Research at MIT, studying the use of nanotechnology and precision medicine approaches for the treatment of brain tumors. He is currently an attending neurosurgeon at Saint Elizabeth's Medical Center in Boston, Massachusetts, with a clinical and research focus on the neurosurgical treatment of patients with primary and metastatic brain and spine tumors.
Dr. Lam's research has been published in internationally recognized journals, including Nature, Science, Cancer Cell, Nature Communications, ACS Nano, Journal of Neurosurgery Spine and Operative Neurosurgery. He has contributed book chapters and reviews to peer-reviewed journals (such as the Frontiers family of journals and others with high Impact Factor). He serves as a peer reviewer and Guest Editor for several international journals. He is an advocate of translational research bridging benchtop to bedside discoveries in order to improve outcomes for patients. He is also engaged in science education, public outreach projects, and is passionate about mentoring the future generation of clinician-scientists.
JTGG will continue to publish more special interview series and build a multi-channel exchange and presentation platform for every excellent scholar.
Respectfully Submitted by the Journal Editorial Office
Journal of Translational Genetics and Genomics